
In patients with HF with reduced ejection fraction, those with frailty had elevated risk for poor outcomes but less likelihood of being on optimal guideline-directed medical therapy, according to new data from the GUIDE-IT trial.
As Healio previously reported, in the main results of GUIDE-IT, a strategy guided by N-terminal pro-B-type natriuretic peptide levels did not benefit patients with HFrEF more than the usual care. For the present post hoc analysis published in JACC: Heart Failure, researchers stratified the cohort into three groups based on frailty index score and compared frailty